Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of TMS-007 in healthy adult males
jRCT2080222603Phase 1
- Sponsor
- TMS Co., Ltd.
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of JX10 (5 arms), sponsored by TMS Co., Ltd. Primary endpoint: Primary safety and tolerability of single ascending doses of TMS-007.
02
Drugs
JX10
Beyond the preview
Go deeper on jRCT2080222603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222603.